ProCE Banner Series

PARP Inhibition in Prostate Cancer: Optimizing Care for Veterans

Join us for this live 1-hour, CME/CE/CPE/AAPA-certified workshop series to learn how healthcare professionals in Veterans Affairs can effectively incorporate combination and single-agent PARP inhibitor regimens into the care of patients with prostate cancer.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This program is intended for oncologists, nurses, pharmacists, physician associates and other healthcare professionals who care for veterans with prostate cancer.

All Events

Upcoming Events

May

23

2024

PARP Inhibition in Prostate Cancer: Optimizing Care for Veterans [Open Registration]

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group FL, West Palm Beach, Florida

Past Events

February

29

2024

PARP Inhibition in Prostate Cancer: Optimizing Care for Veterans

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Private Event, Battle Creek, Michigan

April

24

2024

PARP Inhibition in Prostate Cancer: Optimizing Care for Veterans [Open Registration]

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group NY, Brooklyn, New York

Faculty

ProCE Banner Faculty
Wassim Abida, MD, PhD

Director of Translational Research, Prostate Cancer
Associate Member
Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

ProCE Banner Faculty
Nabil Adra, MD, MS

Associate Professor of Clinical Medicine
Associate Professor of Urology
Service Line Leader, Medical Oncology
Medical Co-Director, IUH Simon Cancer Center
Program Leader, Geintourinary Oncology
Indiana University Simon Comprehensive Cancer Center
Indianapolis, Indiana

ProCE Banner Faculty
Patrick G. Pilie, MD

Assistant Professor
GU Medical Oncology
MD Anderson Cancer Center
Houston, Texas

ProCE Banner Faculty
Benjamin Teply, MD

Associate Professor of Medicine
Division of Hematology/Oncology
University of Nebraska Medical Center
Omaha, Nebraska

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate PARP inhibitors and recent findings into the treatment of patients with prostate cancer.

Target Audience
This program is intended for oncologists, nurses, pharmacists, physician associates and other healthcare professionals who care for veterans with prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the medical need and rationale for PARP inhibitors and PARP inhibitor–based combinations in prostate cancer, with or without DNA damage repair alterations
  • Obtain tumor tissue and assure that it is tested for DNA damage repair alterations to meet the currently approved use of PARP inhibitors for the treatment of prostate cancer 
  • Apply PARP inhibitor–based combination regimens in the treatment of patients with prostate cancer taking into account recent guideline updates, recent data, and expert recommendations
  • Appropriately manage adverse events associated with PARP inhibitor combination regimens to improve quality of life, adherence, and outcomes in patients with prostate cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-032-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.